Bi-specific antibodies in the management of non-Hodgkin Lymphoma

Bi-specific antibodies, such as CD20, CD3 by-specific antibodies, are playing a significant role in the treatment of non-Hodgkin Lymphoma (NHL). They work by targeting both CD20 and CD3, engaging and activating T cells to eliminate malignant B cells. While different bi-specific antibodies are available, some like Inotuzumab have a short half-life and require continuous infusion. Others, such as Epcoritamab and Glofitamab, have longer half-lives and can be dosed less frequently. The efficacy of bi-specific antibodies is comparable to CAR-T therapy, and they are better tolerated with manageable side effects like cytokine release syndrome (CRS). Clinical trials are ongoing to explore combinations with chemotherapy, antibody-drug conjugates, and other immunotherapies. Bi-specific antibodies can be used in different treatment lines, depending on the patient's specific circumstances and disease characteristics.